Behavioral Intervention

Cannabis Abstinence for Improved Cognition and Mental Health

Aurora, CO

N/A

Waitlist Available

Led By J. Megan Ross, Ph.D.

Research Sponsored by University of Colorado, Denver

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Monozygotic (MZ) twin pair, in which both twins are willing to participate

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline to day 42

Awards & highlights

No Placebo-Only Group

Summary

This trial will test if abstaining from cannabis for 42 days can improve cognition and mental health symptoms in identical twins. One twin will abstain and the other won't, to measure the difference.

See full description

Who is the study for?

This trial is for identical twins in Colorado who both use cannabis at least once a week and have done so recently. Both must agree to participate, with similar levels of use (+/- 2 days). They should test positive for THC in urine at the start.Check my eligibility

What is being tested?

The study tests if not using cannabis for 42 days improves thinking skills and mental health symptoms compared to continued use. Twins will be randomly assigned to either stop using cannabis, with incentives (contingency management), or keep their usual habits.See study design

What are the potential side effects?

Since this trial involves stopping cannabis use, side effects may include withdrawal symptoms such as irritability, sleep problems, cravings, restlessness, and physical discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My identical twin and I are both willing to join the study.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline to day 42

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline to day 42

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to day 42 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in attention and executive function

Change in attention performance

Change in episodic memory

+6 more

Secondary study objectives

Change in anxiety symptoms

Change in attention deficit/hyperactivity disorder symptoms

Change in depressive symptoms

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Contingency managementExperimental Treatment1 Intervention

Contingency management (CM) is an incentive-based intervention providing patients with tangible rewards as reinforcement for positive behaviors like abstinence from drug use. Incentives are provided with each urine sample that is drug-free and are increased with each subsequent drug-free urine sample. Participants in the CM condition will receive increasing payments for abstinence: $30 on day 3, $45 on day 5, $60 on day 7, $75 on day 14, $90 on day 21, $105 on day 28, and $120 on day 42. Participants in both conditions also receive increasing payment for visit attendance: $10 on day 1, $15 on day 3, $20 on day 5, $25 on day 7, $30 on day 14, $35 on day 21, $45 on day 28, and $55 on day 42. At the end of the baseline visit, participants in the CM condition will sign a behavioral contract with study staff that clearly outlines expectations as well as the payment schedule.

Group II: No interventionActive Control1 Intervention

Participants in this condition will be monitored and will not receive any compensation for cannabis abstinence.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Contingency management

2006

Completed Phase 4

~1020

0 / 1Eligibility criteria met